<?xml version='1.0' encoding='utf-8'?>
<document id="10435726"><sentence text="Modification of the pharmacokinetics of high-dose cyclophosphamide and cisplatin by antiemetics."><entity charOffset="50-66" id="DDI-PubMed.10435726.s1.e0" text="cyclophosphamide" /><entity charOffset="71-80" id="DDI-PubMed.10435726.s1.e1" text="cisplatin" /><pair ddi="false" e1="DDI-PubMed.10435726.s1.e0" e2="DDI-PubMed.10435726.s1.e0" /><pair ddi="false" e1="DDI-PubMed.10435726.s1.e0" e2="DDI-PubMed.10435726.s1.e1" /></sentence><sentence text="Interpatient variability in exposure to certain chemotherapy agents can influence patient outcome, particularly with high-dose chemotherapy" /><sentence text=" We evaluated the possibility of a pharmacokinetic (PK) drug-drug interaction between the antiemetic agents and high-dose cyclophosphamide, cisplatin and BCNU (CPA/cDDP/BCNU)"><entity charOffset="122-138" id="DDI-PubMed.10435726.s3.e0" text="cyclophosphamide" /><entity charOffset="140-149" id="DDI-PubMed.10435726.s3.e1" text="cisplatin" /><entity charOffset="154-158" id="DDI-PubMed.10435726.s3.e2" text="BCNU" /><entity charOffset="160-163" id="DDI-PubMed.10435726.s3.e3" text="CPA" /><entity charOffset="164-168" id="DDI-PubMed.10435726.s3.e4" text="cDDP" /><entity charOffset="169-172" id="DDI-PubMed.10435726.s3.e5" text="BCNU" /><pair ddi="false" e1="DDI-PubMed.10435726.s3.e0" e2="DDI-PubMed.10435726.s3.e0" /><pair ddi="false" e1="DDI-PubMed.10435726.s3.e0" e2="DDI-PubMed.10435726.s3.e1" /><pair ddi="false" e1="DDI-PubMed.10435726.s3.e0" e2="DDI-PubMed.10435726.s3.e2" /><pair ddi="false" e1="DDI-PubMed.10435726.s3.e0" e2="DDI-PubMed.10435726.s3.e3" /><pair ddi="false" e1="DDI-PubMed.10435726.s3.e0" e2="DDI-PubMed.10435726.s3.e4" /><pair ddi="false" e1="DDI-PubMed.10435726.s3.e0" e2="DDI-PubMed.10435726.s3.e5" /><pair ddi="false" e1="DDI-PubMed.10435726.s3.e1" e2="DDI-PubMed.10435726.s3.e1" /><pair ddi="false" e1="DDI-PubMed.10435726.s3.e1" e2="DDI-PubMed.10435726.s3.e2" /><pair ddi="false" e1="DDI-PubMed.10435726.s3.e1" e2="DDI-PubMed.10435726.s3.e3" /><pair ddi="false" e1="DDI-PubMed.10435726.s3.e1" e2="DDI-PubMed.10435726.s3.e4" /><pair ddi="false" e1="DDI-PubMed.10435726.s3.e1" e2="DDI-PubMed.10435726.s3.e5" /><pair ddi="false" e1="DDI-PubMed.10435726.s3.e2" e2="DDI-PubMed.10435726.s3.e2" /><pair ddi="false" e1="DDI-PubMed.10435726.s3.e2" e2="DDI-PubMed.10435726.s3.e3" /><pair ddi="false" e1="DDI-PubMed.10435726.s3.e2" e2="DDI-PubMed.10435726.s3.e4" /><pair ddi="false" e1="DDI-PubMed.10435726.s3.e2" e2="DDI-PubMed.10435726.s3.e5" /><pair ddi="false" e1="DDI-PubMed.10435726.s3.e3" e2="DDI-PubMed.10435726.s3.e3" /><pair ddi="false" e1="DDI-PubMed.10435726.s3.e3" e2="DDI-PubMed.10435726.s3.e4" /><pair ddi="false" e1="DDI-PubMed.10435726.s3.e3" e2="DDI-PubMed.10435726.s3.e5" /><pair ddi="false" e1="DDI-PubMed.10435726.s3.e4" e2="DDI-PubMed.10435726.s3.e4" /><pair ddi="false" e1="DDI-PubMed.10435726.s3.e4" e2="DDI-PubMed.10435726.s3.e5" /></sentence><sentence text=" Twenty-three self-selected patients treated with high-dose CPA/cDDP/BCNU followed by autologous hematopoietic progenitor cell support (AHPCS) received ondansetron, lorazepam and diphenhydramine as antiemetics"><entity charOffset="152-163" id="DDI-PubMed.10435726.s4.e0" text="ondansetron" /><entity charOffset="165-174" id="DDI-PubMed.10435726.s4.e1" text="lorazepam" /><entity charOffset="179-194" id="DDI-PubMed.10435726.s4.e2" text="diphenhydramine" /><entity charOffset="69-83" id="DDI-PubMed.10435726.s4.e3" text="BCNU" /><entity charOffset="60-74" id="DDI-PubMed.10435726.s4.e4" text="CPA" /><entity charOffset="64-78" id="DDI-PubMed.10435726.s4.e5" text="cDDP" /><pair ddi="false" e1="DDI-PubMed.10435726.s4.e4" e2="DDI-PubMed.10435726.s4.e4" /><pair ddi="false" e1="DDI-PubMed.10435726.s4.e4" e2="DDI-PubMed.10435726.s4.e5" /><pair ddi="false" e1="DDI-PubMed.10435726.s4.e4" e2="DDI-PubMed.10435726.s4.e3" /><pair ddi="false" e1="DDI-PubMed.10435726.s4.e4" e2="DDI-PubMed.10435726.s4.e0" /><pair ddi="false" e1="DDI-PubMed.10435726.s4.e4" e2="DDI-PubMed.10435726.s4.e1" /><pair ddi="false" e1="DDI-PubMed.10435726.s4.e4" e2="DDI-PubMed.10435726.s4.e2" /><pair ddi="false" e1="DDI-PubMed.10435726.s4.e5" e2="DDI-PubMed.10435726.s4.e5" /><pair ddi="false" e1="DDI-PubMed.10435726.s4.e5" e2="DDI-PubMed.10435726.s4.e3" /><pair ddi="false" e1="DDI-PubMed.10435726.s4.e5" e2="DDI-PubMed.10435726.s4.e0" /><pair ddi="false" e1="DDI-PubMed.10435726.s4.e5" e2="DDI-PubMed.10435726.s4.e1" /><pair ddi="false" e1="DDI-PubMed.10435726.s4.e5" e2="DDI-PubMed.10435726.s4.e2" /><pair ddi="false" e1="DDI-PubMed.10435726.s4.e3" e2="DDI-PubMed.10435726.s4.e3" /><pair ddi="false" e1="DDI-PubMed.10435726.s4.e3" e2="DDI-PubMed.10435726.s4.e0" /><pair ddi="false" e1="DDI-PubMed.10435726.s4.e3" e2="DDI-PubMed.10435726.s4.e1" /><pair ddi="false" e1="DDI-PubMed.10435726.s4.e3" e2="DDI-PubMed.10435726.s4.e2" /><pair ddi="false" e1="DDI-PubMed.10435726.s4.e0" e2="DDI-PubMed.10435726.s4.e0" /><pair ddi="false" e1="DDI-PubMed.10435726.s4.e0" e2="DDI-PubMed.10435726.s4.e1" /><pair ddi="false" e1="DDI-PubMed.10435726.s4.e0" e2="DDI-PubMed.10435726.s4.e2" /><pair ddi="false" e1="DDI-PubMed.10435726.s4.e1" e2="DDI-PubMed.10435726.s4.e1" /><pair ddi="false" e1="DDI-PubMed.10435726.s4.e1" e2="DDI-PubMed.10435726.s4.e2" /></sentence><sentence text=" PK parameters for each chemotherapeutic drug in the regimen were compared with those of 129 patients who received exactly the same chemotherapy but an antiemetic regimen substituting prochlorperazine for ondansetron"><entity charOffset="184-200" id="DDI-PubMed.10435726.s5.e0" text="prochlorperazine" /><entity charOffset="205-216" id="DDI-PubMed.10435726.s5.e1" text="ondansetron" /><pair ddi="false" e1="DDI-PubMed.10435726.s5.e0" e2="DDI-PubMed.10435726.s5.e0" /><pair ddi="false" e1="DDI-PubMed.10435726.s5.e0" e2="DDI-PubMed.10435726.s5.e1" /></sentence><sentence text=" In addition, we performed a review of the English literature for reported drug-drug interactions between antiemetics and chemotherapy agents that led to modifications in any PK parameters of the chemotherapy agent" /><sentence text=" Our retrospective study showed that the mean area under the curve (AUC) for both cyclophosphamide (76,600 vs 90,600 microg/ml/min, P=0"><entity charOffset="82-98" id="DDI-PubMed.10435726.s7.e0" text="cyclophosphamide" /></sentence><sentence text="001) and cisplatin (525 vs 648 microg/ml/min, P = 0"><entity charOffset="9-18" id="DDI-PubMed.10435726.s8.e0" text="cisplatin" /></sentence><sentence text="01) were significantly lower in the ondansetron group when compared with the prochlorperazine group"><entity charOffset="36-47" id="DDI-PubMed.10435726.s9.e0" text="ondansetron" /><entity charOffset="77-93" id="DDI-PubMed.10435726.s9.e1" text="prochlorperazine" /><pair ddi="false" e1="DDI-PubMed.10435726.s9.e0" e2="DDI-PubMed.10435726.s9.e0" /><pair ddi="false" e1="DDI-PubMed.10435726.s9.e0" e2="DDI-PubMed.10435726.s9.e1" /></sentence><sentence text=" The AUC for BCNU was not significantly different in both groups (544 vs 677, P = 0"><entity charOffset="13-28" id="DDI-PubMed.10435726.s10.e0" text="BCNU" /></sentence><sentence text="43)" /><sentence text=" We found only one report of modifications of the PK parameters of high-dose chemotherapy agents due to drug-drug interactions with the most commonly used antiemetics in a review of the English literature between 1966 and 1995" /><sentence text=" We concluded that the AUC of high-dose cyclophosphamide and cisplatin are significantly lower when ondansetron, as opposed to prochlorperazine, is used as the antiemetic"><entity charOffset="40-56" id="DDI-PubMed.10435726.s13.e0" text="cyclophosphamide" /><entity charOffset="61-70" id="DDI-PubMed.10435726.s13.e1" text="cisplatin" /><entity charOffset="100-111" id="DDI-PubMed.10435726.s13.e2" text="ondansetron" /><entity charOffset="127-143" id="DDI-PubMed.10435726.s13.e3" text="prochlorperazine" /><pair ddi="false" e1="DDI-PubMed.10435726.s13.e0" e2="DDI-PubMed.10435726.s13.e0" /><pair ddi="false" e1="DDI-PubMed.10435726.s13.e0" e2="DDI-PubMed.10435726.s13.e1" /><pair ddi="false" e1="DDI-PubMed.10435726.s13.e0" e2="DDI-PubMed.10435726.s13.e2" /><pair ddi="false" e1="DDI-PubMed.10435726.s13.e0" e2="DDI-PubMed.10435726.s13.e3" /><pair ddi="false" e1="DDI-PubMed.10435726.s13.e1" e2="DDI-PubMed.10435726.s13.e1" /><pair ddi="false" e1="DDI-PubMed.10435726.s13.e1" e2="DDI-PubMed.10435726.s13.e2" /><pair ddi="false" e1="DDI-PubMed.10435726.s13.e1" e2="DDI-PubMed.10435726.s13.e3" /><pair ddi="false" e1="DDI-PubMed.10435726.s13.e2" e2="DDI-PubMed.10435726.s13.e2" /><pair ddi="false" e1="DDI-PubMed.10435726.s13.e2" e2="DDI-PubMed.10435726.s13.e3" /></sentence><sentence text=" The small sample size and heterogeneity of this group of patients precludes any outcome analysis of pharmacodynamic endpoints such as toxicity or antitumor effect" /><sentence text=" Nevertheless, the potential for interactions between antiemetics and chemotherapy agents should be taken into account when using different high-dose chemotherapy regimens" /><sentence text="" /></document>